Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Orion Corporation, Orion Pharma
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07563738CT.gov A 2-part Phase 1/2 Open-label Trial on ODM-212 | — | Recruiting | — | — | — |
NCT06034860CT.gov Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | — | Terminated | — | — | — |
NCT04665206CT.gov Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT03907852CT.gov Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | — | Active Not Recruiting | — | — | — |
NCT02637531CT.gov A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Orion Corporation, Orion Pharma | P2 | B · 60 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Genmab | P2 | B |
| Fludeoxyglucose | National Cancer Institute (NCI) | P2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
| Tislelizumab | HiFiBiO Therapeutics | P2 | CCC |
| Irinotecan | Genmab | P1/2 | CCC |
| Fluorouracilum | National Cancer Institute (NCI) | P2 | CCC |
+42 more in the Mesothelioma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →